Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.58 |
| ▸ | ITGAV | P06756 | 14/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.56 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.56 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.45 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418152 | 1.00 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418000 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419482 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6417981 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419266 | 0.87 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419319 | 0.84 | PPARD (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6423850 | 0.84 | PPARD (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419323 | 0.84 | PPARD (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6420150 | 0.84 | ITGB3 (0.57) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6418931 | 0.84 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ITGB3 4/4885ITGAV 1/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.